Costs of nosocomial pneumonia caused by meticillin-resistant Staphylococcus aureus

Area of Science:

• Infectious Diseases
• Health Economics
• Clinical Microbiology

Background:

• Nosocomial infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA), impose substantial health and economic burdens.
• Understanding the specific financial impact of MRSA pneumonia compared to its susceptible counterpart is essential for resource allocation and infection control.

Purpose of the Study:

• To quantify and compare the healthcare costs associated with nosocomial MRSA pneumonia versus nosocomial methicillin-susceptible S. aureus (MSSA) pneumonia.
• To determine the attributable costs of MRSA pneumonia to inform hospital policy and infection prevention strategies.

Main Methods:

• A case-control study involving 82 patients (41 MRSA pneumonia cases, 41 MSSA pneumonia controls) admitted between January 2005 and December 2007.
• Patients were meticulously matched for age, disease severity, ICU and non-ICU stay, admission/discharge timing, and pre-pneumonia hospitalization duration.
• Cost analysis included overall and attributable costs per patient, alongside financial loss comparison.

Main Results:

• Overall costs for MRSA pneumonia patients (€60,684) were significantly higher than for MSSA pneumonia patients (€38,731; P=0.01).
• The attributable cost per patient for MRSA pneumonia was €17,282 (P<0.001), with a higher financial loss (€11,704 vs €2,662; P=0.002).
• Hospital mortality was notably higher in the MRSA group (13 deaths) compared to the MSSA group (1 death; P<0.001).

Conclusions:

• Nosocomial MRSA pneumonia incurs significantly higher healthcare costs and financial losses compared to MSSA pneumonia.
• Healthcare personnel must recognize the substantial economic impact of MRSA pneumonia and prioritize the implementation of effective control measures to prevent transmission.